Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GELESIS HOLDINGS, INC.GLS · Entity 109516 | Director | May 06, 2022 | May 09, 2022 |
| Inogen IncINGN · Entity 2083 | EVP, Finance, & CFO | December 01, 2021 | December 03, 2021 |
| Pear Therapeutics, Inc.PEAR · Entity 114512 | Director | February 15, 2023 | February 17, 2023 |
| Sight Sciences, Inc.SGHT · Entity 5537 | Chief Operating Officer | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GELESIS HOLDINGS, INC.
Report date May 06, 2022 · Filed May 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,095 |
Reported balance
After 2022-05-06 transaction · row 1
1 source rowRow 1 · 2022-05-06 · Grant · Acquired 51,095 · Balance 51,095 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F2: These RSUs vest in full on March 1, 2023, subject to the reporting person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.
F2: These RSUs vest in full on March 1, 2023, subject to the reporting person's continued service at such time.
Inogen Inc
Report date December 01, 2021 · Filed December 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,902 |
Last balance in matching sequence
After 2021-12-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-12-01 · Exercise / conversion · Acquired 546 · Balance 34,392 F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error. Row 2 · 2021-12-01 · Tax withholding · Disposed 490 · Balance 33,902 F2: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2021. F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,915 |
Reported balance
After 2021-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-01 · Exercise / conversion · Disposed 546 · Balance 4,915 F3: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F4: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error.
F2: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2021.
F3: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.
F4: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date.
Pear Therapeutics, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 71,428 |
Reported balance
After 2023-02-15 transaction · row 1
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 71,428 · Balance 71,428 |
Sight Sciences, Inc.
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 639,449 |
Reported balance
After 2026-10-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 25,260 · Balance 639,449 F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (i) 214,450 shares of Common Stock, and (ii) 424,999 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs").
F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes (i) 214,450 shares of Common Stock, and (ii) 424,999 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2017 Filed Feb 14, 2017 22:41 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 5,956 | $67.10 | $399,638.07 |
DisclosureSEC source: 0001209191-17-010602 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F2 · price: Represents the weighted average share price of an aggregate total of 5956 shares sold in the price range of $66.47 to $67.31 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 21:39 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 3,333 | $63.40 | $211,315.53 |
DisclosureSEC source: 0001209191-16-154166 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,999 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F2 · price: Represents the weighted average share price of an aggregate total of 3,333 shares sold in the price range of $62.55 to $63.50 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.